ruthenium has been researched along with chrysin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alzahrani, EMS; Attina, A; Gibbins, J; Greco, F; Javed, M; Kabova, E; Osborn, HMI; Pothi, R; Ravishankar, D; Salamah, M; Shankland, K; Strohfeldt, K; Vaiyapuri, R; Vaiyapuri, S; Vallance, TM; Williams, HF | 1 |
| Chakraborty, T; Roy, S; Sil, A | 1 |
2 other study(ies) available for ruthenium and chrysin
| Article | Year |
|---|---|
Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy.
Topics: Animals; Biological Availability; Blood Platelets; Disease Models, Animal; Fibrinolytic Agents; Flavonoids; Hemostasis; Humans; Mice; Platelet Activation; Ruthenium; Thrombosis | 2017 |
Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Female; Flavonoids; Humans; Male; Mammary Neoplasms, Experimental; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Ruthenium; Tumor Suppressor Protein p53 | 2019 |